Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "MITIGLINIDE CALCIUM" patented technology

Mitiglinide Calcium Hydrate is a medicine available in a number of countries worldwide. A list of US medications equivalent to Mitiglinide Calcium Hydrate is available on the Drugs.com website.

Mitiglinide calcium dispersible tablet and preparation method thereof

The invention relates to a mitiglinide calcium dispersible tablet which is characterized by comprising the following materials parting parts by weight: 4-6 parts of mitiglinide calcium, 60-90 parts of starch, 12-18 parts of microcrystalline cellulose, 12.8-19.2 parts of dextrin, 0.8-1.2 parts of magnesium stearate and the balance of pure water. The invention has the advantages of rapid effect of blood sugar, short duration, capability of tabletting, good hardness and better disintegration.
Owner:江西中兴汉方药业有限公司

Rapid-dissolution mitiglinide preparation, and preparation method and detection method thereof

The invention relates to the field of medicinal preparations, and relates to a rapid-dissolution mitiglinide preparation, and a preparation method and a detection method thereof. The prescription of the preparation comprises 4-6 parts of a mitiglinide raw medicine, 25-45 parts of lactose, 15-35 parts of microcrystalline cellulose, 15-35 parts of starch, 1.5-5.5 parts of hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5, 3-10 parts of sodium carboxymethyl starch and 0.05-0.3 parts of magnesium stearate. The rapid-dissolution mitiglinide preparation has the advantages of easy obtaining of auxiliary materials, low cost, simple preparation method, fast in vitro digestion, realization of the 10min dissolution rate of various dissolution media reaching 90% or above, and stable quality.
Owner:YICHANG HEC CHANGJIANG PHARMA CO LTD

Detection method for mitiglinide calcium R-isomer

The invention relates to a detection method for mitiglinide calcium R-isomer. According to the method, high performance liquid chromatography is adopted. The method comprises the following steps of: 1) the preparation of a test sample solution: a proper amount of a mitiglinide calcium bulk pharmaceutical chemical test sample is taken, and is precisely weighed, a mobile phase is added to the mitiglinide calcium bulk pharmaceutical chemical test sample, so that a solution containing 0.2 mg of the mitiglinide calcium bulk pharmaceutical chemical test sample per 1ml can be prepared, and the solution is uniformly shaken, so that the test sample solution can be obtained; 2) the preparation of a mitiglinide calcium reference substance solution: a proper amount of mitiglinide calcium reference substance is taken, is precisely weighed, a mobile phase is added to the mitiglinide calcium reference substance, so that a solution containing 0.2 mg of the mitiglinide calcium reference substance per 1ml can be prepared, and the solution is uniformly shaken, so that the mitiglinide calcium reference substance solution is obtained; and (3) the preparation of a mitiglinide calcium R-isomer referencesubstance solution: a proper amount of mitiglinide calcium R-isomer reference substance is taken, and is precisely weighed, a mobile phase is added, so that a solution containing 0.2 mg of mitiglinidecalcium R-isomer reference substance per 1ml can be prepared, and the solution is uniformly shaken, so that the mitiglinide calcium R-isomer reference substance solution can be obtained; and 4) determination: 20 microliters of the solutions in the step 1), the step 2) and the step 3) are separately injected into a high performance liquid chromatograph, so that chromatograms can be obtained, and the content of the mitiglinide calcium R-isomer in the mitiglinide calcium bulk pharmaceutical chemical is calculated according to peak areas in the chromatograms and through a normalization method.
Owner:JIANGXI JINSHUIBAO PHARM CO LTD +1

Method for preparing hypoglycemic drug mitiglinide calcium

The invention relates to a method for preparing a hypoglycemic drug mitiglinide calcium. According to the method, under the temperature of -5 DEG C-10 DEG C, 30-60g of 2-benzylidene-3-(cis-perhydro-isoindolyl-2-carbonyl)propionic acid is dissolved in 200-500 milliliters of a reaction solvent, 2-5 g of a S-configuration aminoalcohol catalyst, 8-15 g of a borohydride and 15-25 g of trimethylchlorosilane are added, the materials are stirred for a reaction for 4-8 hours, pressure reduction is carried out for steaming the solvent, 400-600 milliliters of water and 4-6 milliliters of hydrochloric acid are added, ethyl acetate is used for extraction, an extract is merged, the extract is dried and concentrated to obtain a concentrate, the concentrate is dissolved in 400-600 mL of ethanol with mass concentration of 75-95%, 3-5 g of sodium hydroxide is added, after stirring and dissolving the materials, 8-12 g of calcium chloride is added, precipitate is obtained, and then the precipitate is subjected to pumping filtration to obtain mitiglinide calcium. The preparing method has the advantages of simple process, energy saving and environmental protection, can greatly increase the overall yield and obviously reduce the production cost, is easy to industrial production, is an innovation of a medicine for treating diabetes, and has large economic and social benefits.
Owner:HENAN UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products